Phase II/III Trials of Viracept start.
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001769:Blood / Q000382:microbiology; D018791:CD4 Lymphocyte Count; D004359:Drug Therapy, Combination; D006678:HIV / Q000302:isolation & purification; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007546:Isoquinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019259:Lamivudine / Q000008:administration & dosage; D019888:Nelfinavir; D010865:Pilot Projects; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage; D018119:Stavudine / Q000008:administration & dosage; D013451:Sulfonic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D015215:Zidovudine / Q000008:administration & dosage
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D018894:Reverse Transcriptase Inhibitors; D013451:Sulfonic Acids; D019259:Lamivudine; D015215:Zidovudine; D018119:Stavudine; D019888:Nelfinavir